Key Findings: EU Project MODICA Transforms Bioprocess Manufacturing with Adaptive Digital Twins
A research and development project by MODICA P.S.A., co-funded by EU funds, is introducing an innovative Adaptive Digital Twin (ADT) for bioprocess modeling. This cutting-edge system seamlessly integrates with modular bioreactor hardware components, aiming to dramatically improve the efficiency and flexibility of biopharmaceutical manufacturing by enabling efficient bioprocess scaling and semi-continuous operation, which have historically been challenging.
Technical and Clinical Details: How ADT Optimizes Bioprocesses
- Adaptive Digital Twin (ADT): The ADT is a virtual model that learns autonomously based on real-time data, reflecting the dynamic behavior of the bioprocess. This allows it to adapt to changes in process conditions and unpredictable variations in real-time, consistently maintaining optimal operating conditions.
- Integration with Modular Bioreactor Hardware: The ADT system is integrated with highly flexible modular bioreactors. This enables rapid and easy process scaling from R&D stages to large-scale production, allowing for flexible manufacturing setups tailored to different products and production requirements.
- Efficient Scaling: By reducing physical trial-and-error and enabling simulation of various scale-up strategies in a virtual environment, development time and costs are significantly reduced. This accelerates the time-to-market for new products.
- Enabling Semi-Continuous Operation: The ADT enhances process stability and predictability, allowing for optimization of semi-continuous operation (e.g., fed-batch or perfusion culture). This improves productivity, increases facility utilization, and reduces manufacturing costs.
- Simulation, Monitoring, and Optimization: The ADT provides powerful tools for simulating complex bioprocess behaviors, monitoring them in real-time, and continuously optimizing them. This works closely with Process Analytical Technology (PAT) to enhance quality control.
Background and Industry Context: Bottlenecks in Biopharmaceutical Manufacturing and the Need for Digitalization
While biopharmaceutical development is accelerating, scalability, efficiency, and flexibility of manufacturing processes remain major challenges. In particular, traditional batch manufacturing is inefficient, and there is a strong demand for a shift towards continuous manufacturing. Digital twin technology is recognized as a key enabler for this transition, making processes more controllable and predictable. The EU supports R&D in this area to strengthen the competitiveness of biomanufacturing within the region.
Future Outlook: Realizing Sustainable and Agile Biomanufacturing
The ADT system developed by the MODICA project has the potential to establish a more sustainable, agile, and cost-effective production model in biopharmaceutical manufacturing. The widespread adoption of this technology will facilitate rapid development and market entry of new drugs, contributing to improved patient access. In the future, such adaptive digital twins are expected to be widely adopted as a core technology for next-generation smart biomanufacturing facilities.
Source: https://modica.bio/eu-project
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments